Stewart D J, Grewaal D, Redmond M D, Mikhael N Z, Montpetit V A, Goel R, Green R M
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
Cancer Chemother Pharmacol. 1993;32(5):368-72. doi: 10.1007/BF00735921.
Autopsy tissues were collected from ten patients who had received etoposide, 150-3480 mg, from 1 to 412 days antemortem and from five patients who had received teniposide, 234-1577 mg, from 3 to 52 days antemortem. Tissues were assayed for etoposide and teniposide using high-pressure liquid chromatography with electrochemical detection. Etoposide was detectable in tissues of three of four patients dying < 5 days after their last etoposide treatments to cumulative doses of 150-432 (median, 280) mg but was detectable in tissues of only one of six patients dying 7-412 (median, 37) days after their last etoposide treatment to a cumulative dose of 607-3600 (median, 1553) mg. The highest tissue concentrations were in the small bowel, prostate, thyroid, bladder, spleen, and testicle. Intermediate concentrations were found in the lymph node, skeletal muscle, adrenal gland, stomach, tumor, liver, lung, pancreas, and kidney, and the lowest concentrations were found in the heart, brain, diaphragm, vagina, and esophagus. Teniposide was detectable in one patient dying 3 days after a cumulative teniposide dose of 576 mg (spleen, prostate, heart > large bowel, liver, pancreas > thyroid, adrenal, stomach, small bowel, bladder, testicle, and skeletal muscle) but was not detectable in any tissue from four patients dying 5-52 (median, 8) days after their last treatment to a cumulative teniposide dose of 234-1577 (median, 520) mg. The very short tissue half-life contrasts with our previous observations for human autopsy tissue concentrations of mitoxantrone, doxorubicin, menogaril metabolites, diaziquone, and amsacrine. The short tissue half-life may help explain the schedule dependency of epipodophyllotoxin efficacy and may also help explain the lack of visceral toxicity of these compounds.
尸检组织取自10例生前1至412天接受过150 - 3480毫克依托泊苷治疗的患者,以及5例生前3至52天接受过234 - 1577毫克替尼泊苷治疗的患者。使用带电化学检测的高压液相色谱法对组织中的依托泊苷和替尼泊苷进行检测。在末次依托泊苷治疗后<5天死亡的4例患者中,有3例的组织中可检测到依托泊苷,累积剂量为150 - 432(中位数,280)毫克;而在末次依托泊苷治疗后7 - 412(中位数,37)天死亡的6例患者中,只有1例的组织中可检测到依托泊苷,累积剂量为607 - 3600(中位数,1,553)毫克。最高组织浓度出现在小肠、前列腺、甲状腺、膀胱、脾脏和睾丸。中等浓度出现在淋巴结、骨骼肌、肾上腺、胃、肿瘤、肝脏、肺、胰腺和肾脏,最低浓度出现在心脏、大脑、膈肌、阴道和食管。在累积替尼泊苷剂量达576毫克后3天死亡的1例患者中可检测到替尼泊苷(脾脏、前列腺、心脏>大肠、肝脏、胰腺>甲状腺、肾上腺、胃、小肠、膀胱、睾丸和骨骼肌),但在末次治疗后5 - 52(中位数,8)天死亡的4例患者中,累积替尼泊苷剂量为234 - 1577(中位数,520)毫克,其任何组织中均未检测到替尼泊苷。这种非常短的组织半衰期与我们之前对人尸检组织中米托蒽醌、多柔比星、美诺加里尔代谢物、重氮醌和安吖啶浓度的观察结果形成对比。短的组织半衰期可能有助于解释表鬼臼毒素疗效的给药方案依赖性,也可能有助于解释这些化合物缺乏内脏毒性的原因。